Cadence Pharmaceuticals, (FRA:QEW) Forward PE Ratio : 0.00 (As of Sep. 24, 2024)

View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Forward PE Ratio?

Cadence Pharmaceuticals,'s Forward PE Ratio for today is 0.00.

Cadence Pharmaceuticals,'s PE Ratio without NRI for today is 0.00.

Cadence Pharmaceuticals,'s PE Ratio for today is 0.00.

Cadence Pharmaceuticals, Forward PE Ratio Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Forward PE Ratio Chart

Cadence Pharmaceuticals, Annual Data

Trend

Forward PE Ratio

Cadence Pharmaceuticals, Quarterly Data

Forward PE Ratio

Competitive Comparison of Cadence Pharmaceuticals,'s Forward PE Ratio

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cadence Pharmaceuticals,'s Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s Forward PE Ratio falls into.

Cadence Pharmaceuticals, Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Cadence Pharmaceuticals, (FRA:QEW) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Cadence Pharmaceuticals, Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cadencepharm.com

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, Headlines

No Headlines